8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2.4B | $771M | 0.0% | 65.6% | — | $9.0B | $619M |
| 2024 | $2.3B | $859M | 0.0% | 57.1% | — | $7.6B | $929M |
| 2023 | $2.4B | $1.1B | 0.0% | 63.4% | — | $6.1B | $477M |
| 2022 | $2.2B | $43M | 0.0% | 13.7% | — | $7.1B | $1.7B |
| 2021 | $2.3B | $620M | 0.0% | 62.5% | — | $7.1B | $1.5B |
| 2020 | $2.1B | $975M | 0.0% | 75.2% | — | $5.8B | $1.0B |
| 2019 | $1.8B | $2.3B | 0.0% | 144.6% | — | $6.2B | $246M |
| 2018 | $1.8B | $1.4B | 0.0% | 76.0% | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $631M | $295M | 0.0% | 89.3% | — | $9.0B | $586M |
| Dec '25 | $622M | $214M | 0.0% | 62.4% | — | $9.0B | $619M |
| Sep '25 | $609M | $288M | 0.0% | 70.1% | — | $8.9B | $939M |
| Jun '25 | $579M | $30M | 0.0% | 36.3% | — | $8.0B | $632M |
| Mar '25 | $568M | $239M | 0.0% | 94.0% | — | $7.6B | $1.1B |
| Dec '24 | $594M | $208M | 0.0% | 60.9% | — | $7.6B | $929M |
| Sep '24 | $565M | $544M | 0.0% | 130.2% | — | $7.6B | $950M |
| Jun '24 | $537M | $102M | 0.0% | 50.2% | — | $7.6B | $1.8B |
| Mar '24 | $568M | $5M | 0.0% | -13.0% | — | $6.1B | $843M |
| Dec '23 | $596M | $494M | 0.0% | 102.8% | — | $6.1B | $477M |
| Sep '23 | $536M | $72M | 0.0% | 28.2% | — | $6.1B | $936M |
| Jun '23 | $538M | $228M | 0.0% | 46.2% | — | $7.1B | $2.2B |
| Mar '23 | $684M | $341M | 0.0% | 70.0% | — | $7.1B | $2.0B |
| Dec '22 | $566M | -$456M | 0.0% | -85.3% | — | $7.1B | $1.7B |
| Sep '22 | $573M | $143M | 0.0% | 33.5% | — | $7.1B | $992M |
| Jun '22 | $536M | $305M | 0.0% | 70.5% | — | $7.1B | $2.1B |
| Mar '22 | $562M | $52M | 0.0% | 39.1% | — | $7.1B | $1.8B |
| Dec '21 | $576M | $8M | 0.0% | 26.6% | — | $7.1B | $1.5B |
| Sep '21 | $586M | $102M | 0.0% | 51.7% | — | $7.1B | $1.8B |
| Jun '21 | $555M | $441M | 0.0% | 134.2% | — | $5.8B | $1.1B |
How the market has priced RPRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Royalty Pharma Plc's revenue has grown 2.3% per year, and net income declined 4.6% per year. These are computed facts, not advice.
As of FY2025, Royalty Pharma Plc reported $9.0B of total debt against $619M of cash; operating income covered interest expense 5.1×.
In FY2025, gross margin was —, operating margin 65.6%, and net margin 32.4%.
As of Jun '26, Royalty Pharma Plc traded at a price-to-earnings ratio of about 31.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.